

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and a Waiver under 21 U.S.C. §355 (n)(4)

Stacey Berg, M.D.

Committee: The Pediatric Subcommittee of the Oncologic Drugs Advisory Committee

Meeting Date: March 14, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to the discussions of clinical trials of methotrexate and daunomycin to be conducted under the Best Pharmaceuticals for Children Act. Methotrexate is sponsored by Mayne Pharma USA, a Mayne Group Ltd. Cerubidine (daunorubicin, daunomycin) is sponsored by Bedford Laboratories, a division of Ben Venue Laboratories, Inc., a wholly owned subsidiary of Boehringer Ingelheim Corporation, the U.S. affiliate of Boehringer Ingelheim GmbH, I am eligible to receive waiver under 21 U.S.C. §355(n)(4).

Type of Interest	Nature	Magnitude
Stock	Competitor	Valued from \$5,001 to \$25,000

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

/s/
Signature of SGE

2/13/06
Date